Latest news
Amylyx Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $26.7, Implies 22% Upside - TradingViewTradingView · Thu, 06 Aug 2026 23:20:04 GMTAmylyx Pharmaceuticals Q2 Earnings Call Highlights - TradingViewTradingView · Thu, 06 Aug 2026 15:04:22 GMTAMLX: LUCIDITY phase III data for avexitide in PBH expected soon; launch readiness and cash runway strong - TradingViewTradingView · Thu, 06 Aug 2026 14:07:06 GMTAmylyx Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 13:02:42 GMTAmylyx Pharmaceuticals Q2 posts higher than expected loss - TradingViewTradingView · Thu, 06 Aug 2026 11:26:41 GMTAMLX: Q2 2026 net loss rose to $43.4M; cash runway extends into 2028 with key Phase 3 data expected soon - TradingViewTradingView · Thu, 06 Aug 2026 11:04:58 GMTAMLX: LUCIDITY trial for avexitide nears topline data; cash runway extends into 2028 - TradingViewTradingView · Thu, 06 Aug 2026 11:03:57 GMTAmylyx Pharmaceuticals reports Q2 net loss $43.4M, cash $250.8M, runway into 2028 - TradingViewTradingView · Thu, 06 Aug 2026 11:03:01 GMT